Fig. 7
Administration of an analogous CSF1R inhibitor, PLX3397 (75 ppm and 600 ppm), to 5xFAD mice. a Experimental design. b Terminal PK of wild-type and 5xFAD groups treated with PLX3397. c, d Confocal images of tissue stained for dense-core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in red) in 600 ppm PLX3397-treated and control mice. Scale bar = 75 μm. e–h Sections of the retrosplenial (RS) and somatosensory (SS) cortex, respectively, stained for dense-core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in red) in mice treated with control or 75 ppm PLX3397. Scale bar = 75 μm. i Quantification of IBA1+ cell number in the RS and SS cortex. (SS Cortex: PLX5622 v 5xFAD + PLX5622, p = 0.045) Two-way ANOVA with Tukey’s post hoc test; n = 4 for Wild-type, n = 6 for PLX3397, n = 6 for 5xFAD, n = 4 for 5xFAD + PLX3397. j–k, Quantification of cortical plaque number and volume, respectively, revealing no change in these measures with 75 ppm PLX3397 treatment in 5xFAD mice. Two-tailed independent t-test; n = 4–5 for 5xFAD, n = 4–5 for 5xFAD + PLX3397. Statistical significance is denoted by *p < 0.05. Statistical trends are denoted by #p < 0.10. Error bars indicate SEM
